Literature DB >> 34755388

A group-sequential randomized trial design utilizing supplemental trial data.

Ales Kotalik1, David M Vock2, Brian P Hobbs3, Joseph S Koopmeiners2.   

Abstract

Definitive clinical trials are resource intensive, often requiring a large number of participants over several years. One approach to improve the efficiency of clinical trials is to incorporate historical information into the primary trial analysis. This approach has tremendous potential in the areas of pediatric or rare disease trials, where achieving reasonable power is difficult. In this article, we introduce a novel Bayesian group-sequential trial design based on Multisource Exchangeability Models, which allows for dynamic borrowing of historical information at the interim analyses. Our approach achieves synergy between group sequential and adaptive borrowing methodology to attain improved power and reduced sample size. We explore the frequentist operating characteristics of our design through simulation and compare our method to a traditional group-sequential design. Our method achieves earlier stopping of the primary study while increasing power under the alternative hypothesis but has a potential for type I error inflation under some null scenarios. We discuss the issues of decision boundary determination, power and sample size calculations, and the issue of information accrual. We present our method for a continuous and binary outcome, as well as in a linear regression setting.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  borrowing strength; data aggregation; exchangeability; group-sequential trial

Mesh:

Year:  2021        PMID: 34755388      PMCID: PMC8795487          DOI: 10.1002/sim.9249

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  34 in total

1.  Statistical design considerations for trials that study multiple indications.

Authors:  Alexander M Kaizer; Joseph S Koopmeiners; Nan Chen; Brian P Hobbs
Journal:  Stat Methods Med Res       Date:  2020-12-02       Impact factor: 3.021

2.  Determining the effective sample size of a parametric prior.

Authors:  Satoshi Morita; Peter F Thall; Peter Müller
Journal:  Biometrics       Date:  2007-08-30       Impact factor: 2.571

3.  Clinical trials in rare disease: challenges and opportunities.

Authors:  Erika F Augustine; Heather R Adams; Jonathan W Mink
Journal:  J Child Neurol       Date:  2013-09       Impact factor: 1.987

4.  Incorporating Adult Evidence Into Pediatric Research and Practice: Bayesian Designs to Expedite Obtaining Child-Specific Evidence.

Authors:  Srinivas Murthy; Patricia Fontela; Scott Berry
Journal:  JAMA       Date:  2021-04-26       Impact factor: 56.272

5.  The Role of Nicotine in the Effects of Maternal Smoking during Pregnancy on Lung Development and Childhood Respiratory Disease. Implications for Dangers of E-Cigarettes.

Authors:  Eliot R Spindel; Cindy T McEvoy
Journal:  Am J Respir Crit Care Med       Date:  2016-03-01       Impact factor: 21.405

6.  Equipoise and the ethics of clinical research.

Authors:  B Freedman
Journal:  N Engl J Med       Date:  1987-07-16       Impact factor: 91.245

7.  Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials.

Authors:  Brian P Hobbs; Bradley P Carlin; Sumithra J Mandrekar; Daniel J Sargent
Journal:  Biometrics       Date:  2011-03-01       Impact factor: 2.571

8.  Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.

Authors:  Bruce E Silverstein; Catherine Allaire; Kirk M Bateman; Lynne S Gearinger; Timothy W Morris; Timothy L Comstock
Journal:  Clin Ther       Date:  2011-01       Impact factor: 3.393

9.  Reduced nicotine content cigarettes and use of alternative nicotine products: exploratory trial.

Authors:  Dorothy K Hatsukami; Xianghua Luo; Laura Dick; Margarita Kangkum; Sharon S Allen; Sharon E Murphy; Stephen S Hecht; Peter G Shields; Mustafa al'Absi
Journal:  Addiction       Date:  2016-11-02       Impact factor: 6.526

Review 10.  Use of historical control data for assessing treatment effects in clinical trials.

Authors:  Kert Viele; Scott Berry; Beat Neuenschwander; Billy Amzal; Fang Chen; Nathan Enas; Brian Hobbs; Joseph G Ibrahim; Nelson Kinnersley; Stacy Lindborg; Sandrine Micallef; Satrajit Roychoudhury; Laura Thompson
Journal:  Pharm Stat       Date:  2013-08-05       Impact factor: 1.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.